Celltech rises on encouraging test results
Wednesday 10 May 1995
Clinical trials for three promising new medical compounds are continuing to go well for Celltech, the biotechnology company, which floated at 250p nearly 18 months ago.
The encouraging progress, combined with news that interim losses have been cut by £300,000 to £4.1m, was well received by the stock market, which marked up Celltech's shares by 2.5p to 307p yesterday.
Peter Fellner, chief executive, said: "The trials are very much on track and there have been no unpleasant surprises as some others in the sector have had." The second phase of studies to determine whether the compounds actually work is now under way, he said.
None of the expected side-effects have shown up in a new oral treatment for mild and moderate asthma, code-named CDP 840, which could be submitted for licensing in 1998. The potential for the drug, being developed with Merck, should be clearer by the end of this year, Mr Fellner said. The market is huge, with $6bn being spent on existing products like Ventolin and Tilade last year.
But, if tests go well, Celltech's first approvals are likely to be for a drug being developed with Bayer to combat inflammatory bowel disorders, called CDP 571, and an anti-leukaemia compound that American Home Products is backing, entitled CDP 771. Mr Fellner said filings could come as early as 1997.
Celltech differentiates itself from other recent biotechnology offerings by its higher levels of external income. Turnover from its business making antibodies for groups like Roche and Johnson & Johnson rose from £6.5m to £7.2m in the six months to March. With interest income - £900,000 in the half-year, down from £1m before - that is meant to fund half the research and development budget, with the rest coming from big drug company partners. Mr Fellner was pleased with the fall in half-year losses, despite having raised R&D spending by £1m to £8.8m last year.
- 1 Tidal launch: The most pretentious lines from Alicia Keys' valedictory speech
- 2 Britain First 'acting like Ukip henchmen' by invading meeting of activists in revenge for pub protest against Nigel Farage
- 3 Katie Hopkins attacked me on Twitter — so I reported her to the police for inciting racial hatred
- 4 Tidal: Jay Z's Spotify rival streaming service criticised for making wealthy artists even richer
- 5 Brixton squat flats now costing up to £3k per month show how out of control rent is in London
Britain First 'acting like Ukip henchmen' by invading meeting of activists in revenge for pub protest against Nigel Farage
Costa Concordia: Shipment of Mob drugs was hidden aboard cruise liner when it hit rocks off Italian coast, investigators say
Brixton squat flats now costing up to £3k per month show how out of control rent is in London
A new (old) cure for MRSA? Revolting recipe from the Dark Ages may be key to defeat infection
Turkey power cut: Prime Minister says nationwide blackout could be caused by terrorists
Ukip supporters are 55 or older, white and socially conservative, finds British Social Attitudes Report
Street preacher quoting from the Bible fined for calling homosexuality an 'abomination'
Woman filmed launching racist tirade against men on the Tube for speaking in 'own lingo'
The West has it totally wrong on Lee Kuan Yew
David Cameron calls Labour 'hopeless, sneering socialists' while announcing 7-day NHS plans
Revealed: Putin's army of pro-Kremlin bloggers
iJobs Money & Business
£45000 - £50000 per annum + benefits : Ashdown Group: A highly successful, glo...
£50,000 - £55,000: Neil Pavier: Are you a professionally qualified commercial ...
£45,000 - £55,000: Loren Hughes: Are you looking for a new opportunity that wi...
Circa £45,000-£50,000 + benefits: Sheridan Maine: Are you a newly qualified ac...